Kristian Kragholm1, Sharif A Halim1, Qinghong Yang1, Phillip J Schulte1, Judith S Hochman1, Chiara Melloni1, Kenneth W Mahaffey1, David J Moliterno1, Robert A Harrington1, Harvey D White1, Paul W Armstrong1, E Magnus Ohman1, Frans Van de Werf1, Pierluigi Tricoci1, John H Alexander1, Robert P Giugliano1, L Kristin Newby2. 1. From the Duke Clinical Research Institute, Durham, NC (K.K., S.A.H., Q.Y., P.J.S., C.M., E.M.O., P.T., J.H.A., L.K.N.); Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, New York University School of Medicine and NYU Langone Medical Center, New York, NY (J.S.H.); Department of Medicine, Stanford University, Stanford, CA (K.W.M., R.A.H.); Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY (D.J.M.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Department of Medicine, University of Alberta, Edmonton, Canada (P.W.A.); Department of Cardiology, University Hospitals Leuven, Leuven, Belgium (F.V.d.W.); and Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G.). 2. From the Duke Clinical Research Institute, Durham, NC (K.K., S.A.H., Q.Y., P.J.S., C.M., E.M.O., P.T., J.H.A., L.K.N.); Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, New York University School of Medicine and NYU Langone Medical Center, New York, NY (J.S.H.); Department of Medicine, Stanford University, Stanford, CA (K.W.M., R.A.H.); Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY (D.J.M.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.D.W.); Department of Medicine, University of Alberta, Edmonton, Canada (P.W.A.); Department of Cardiology, University Hospitals Leuven, Leuven, Belgium (F.V.d.W.); and Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (R.P.G.). kristin.newby@duke.edu.
Abstract
BACKGROUND: Adequate representation by sex in trials allows generalizability of results. We examined representation of women in clinical trials during a 17-year period in which inclusion criteria were broadened and federal mandates for representativeness were launched. METHODS AND RESULTS: Using mixed models, we studied sex-stratified temporal trends in enrollment, clinical characteristics, treatment, and outcomes among 76 148 non-ST-segment elevation acute coronary syndrome patients using patient-level data merged from 11 phase III trials conducted from 1994 to 2010. Overall, 33.3% of patients were women, which changed minimally over time. Women were consistently 4 to 5 years older than men (median age 68 [interquartile range 61-75] versus 64 [interquartile range 56-72] years) and more frequently had diabetes mellitus, hypertension, and heart failure; men more frequently had prior myocardial infarction and revascularization. GRACE risk scores increased over time for both sexes with the inclusion of older patients with more comorbidities. Use of percutaneous coronary intervention, in-hospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, β-blockers, and lipid-lowering drugs also increased among both sexes. Kaplan-Meier estimates of 6-month mortality declined from 7.0% [95% confidence interval 6.5%-7.6%] to 4.5% [95% confidence interval 4.0%-5.0%] among women and 6.3% [95% confidence interval 6.0%-6.7%] to 3.1% [95% confidence interval 2.9%-3.4%] among men during the 17-year period. CONCLUSIONS: The relative proportion of women in non-ST-segment elevation acute coronary syndrome trials changed minimally over time. Nevertheless, in parallel with men, use of evidence-based care and outcomes improved significantly over time among women.
RCT Entities:
BACKGROUND: Adequate representation by sex in trials allows generalizability of results. We examined representation of women in clinical trials during a 17-year period in which inclusion criteria were broadened and federal mandates for representativeness were launched. METHODS AND RESULTS: Using mixed models, we studied sex-stratified temporal trends in enrollment, clinical characteristics, treatment, and outcomes among 76 148 non-ST-segment elevation acute coronary syndromepatients using patient-level data merged from 11 phase III trials conducted from 1994 to 2010. Overall, 33.3% of patients were women, which changed minimally over time. Women were consistently 4 to 5 years older than men (median age 68 [interquartile range 61-75] versus 64 [interquartile range 56-72] years) and more frequently had diabetes mellitus, hypertension, and heart failure; men more frequently had prior myocardial infarction and revascularization. GRACE risk scores increased over time for both sexes with the inclusion of older patients with more comorbidities. Use of percutaneous coronary intervention, in-hospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, β-blockers, and lipid-lowering drugs also increased among both sexes. Kaplan-Meier estimates of 6-month mortality declined from 7.0% [95% confidence interval 6.5%-7.6%] to 4.5% [95% confidence interval 4.0%-5.0%] among women and 6.3% [95% confidence interval 6.0%-6.7%] to 3.1% [95% confidence interval 2.9%-3.4%] among men during the 17-year period. CONCLUSIONS: The relative proportion of women in non-ST-segment elevation acute coronary syndrome trials changed minimally over time. Nevertheless, in parallel with men, use of evidence-based care and outcomes improved significantly over time among women.
Authors: Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey Journal: N Engl J Med Date: 2011-11-13 Impact factor: 91.245
Authors: John H Alexander; Renato D Lopes; Stefan James; Rakhi Kilaru; Yaohua He; Puneet Mohan; Deepak L Bhatt; Shaun Goodman; Freek W Verheugt; Marcus Flather; Kurt Huber; Danny Liaw; Steen E Husted; Jose Lopez-Sendon; Raffaele De Caterina; Petr Jansky; Harald Darius; Dragos Vinereanu; Jan H Cornel; Frank Cools; Dan Atar; Jose Luis Leiva-Pons; Matyas Keltai; Hisao Ogawa; Prem Pais; Alexander Parkhomenko; Witold Ruzyllo; Rafael Diaz; Harvey White; Mikhail Ruda; Margarida Geraldes; Jack Lawrence; Robert A Harrington; Lars Wallentin Journal: N Engl J Med Date: 2011-07-24 Impact factor: 91.245
Authors: Philippe Gabriel Steg; Sanjit S Jolly; Shamir R Mehta; Rizwan Afzal; Denis Xavier; Hans-Jurgen Rupprecht; Jose L López-Sendón; Andrzej Budaj; Rafael Diaz; Alvaro Avezum; Petr Widimsky; Sunil V Rao; Susan Chrolavicius; Brandi Meeks; Campbell Joyner; Janice Pogue; Salim Yusuf Journal: JAMA Date: 2010-08-31 Impact factor: 56.272
Authors: Chiara Melloni; Jeffrey S Berger; Tracy Y Wang; Funda Gunes; Amanda Stebbins; Karen S Pieper; Rowena J Dolor; Pamela S Douglas; Daniel B Mark; L Kristin Newby Journal: Circ Cardiovasc Qual Outcomes Date: 2010-02-16
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Nancy M Allen LaPointe; Anita Y Chen; Matthew T Roe; David J Cohen; Deborah B Diercks; James W Hoekstra; Francis M Fesmire; W Brian Gibler; E Magnus Ohman; Eric D Peterson Journal: Am J Cardiol Date: 2009-09-26 Impact factor: 2.778
Authors: Eric D Peterson; Bimal R Shah; Lori Parsons; Charles V Pollack; William J French; John G Canto; C Michael Gibson; William J Rogers Journal: Am Heart J Date: 2008-11-01 Impact factor: 4.749
Authors: Robert P Giugliano; Jennifer A White; Christoph Bode; Paul W Armstrong; Gilles Montalescot; Basil S Lewis; Arnoud van 't Hof; Lisa G Berdan; Kerry L Lee; John T Strony; Steven Hildemann; Enrico Veltri; Frans Van de Werf; Eugene Braunwald; Robert A Harrington; Robert M Califf; L Kristin Newby Journal: N Engl J Med Date: 2009-03-30 Impact factor: 91.245
Authors: William R Lewis; A Gray Ellrodt; Eric Peterson; Adrian F Hernandez; Kenneth A LaBresh; Christopher P Cannon; Wenqin Pan; Gregg C Fonarow Journal: Circ Cardiovasc Qual Outcomes Date: 2009-10-27
Authors: Markella V Zanni; Kathleen Fitch; Corinne Rivard; Laura Sanchez; Pamela S Douglas; Steven Grinspoon; Laura Smeaton; Judith S Currier; Sara E Looby Journal: HIV Clin Trials Date: 2017-03
Authors: Kshipra Hemal; Neha J Pagidipati; Adrian Coles; Rowena J Dolor; Daniel B Mark; Patricia A Pellikka; Udo Hoffmann; Sheldon E Litwin; Melissa A Daubert; Svati H Shah; Kevin Ariani; Renée P Bullock-Palmer; Beth Martinez; Kerry L Lee; Pamela S Douglas Journal: JACC Cardiovasc Imaging Date: 2016-04
Authors: Amelia M Stanton; Georgia R Goodman; Gregory K Robbins; Sara E Looby; Marcel Williams; Christina Psaros; Greer Raggio Journal: J Women Aging Date: 2022-02-24
Authors: Caitlin A Moran; Anandi N Sheth; C Christina Mehta; David B Hanna; Deborah R Gustafson; Michael W Plankey; Wendy J Mack; Phyllis C Tien; Audrey L French; Elizabeth T Golub; Arshed Quyyumi; Robert C Kaplan; Ighovwerha Ofotokun Journal: AIDS Date: 2018-05-15 Impact factor: 4.632